Brief, Non-Pharmacological, Interventions for Pediatric Anxiety: Meta-Analysis and Evidence Base Status.

Brief, Non-Pharmacological, Interventions for Pediatric Anxiety: Meta-Analysis and Evidence Base Status.
复制标题

儿科焦虑症的简短非药理学干预措施:荟萃分析和证据基础状况。

DOI:
10.1080/15374416.2020.1738237
复制
发表时间:
2020
期刊:
Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53
影响因子:
--
通讯作者:
Schleider,Jessica
Schleider,Jessica
中科院分区:
--
文献类型:
--
作者:
Stoll,RyanD;Pina,ArmandoA;Schleider,Jessica

文献摘要

相似文献

1998年,Ost出版了《特定恐惧症的一次性治疗--一种快速有效的方法》(瑞典语),提出了简短、密集和集中的心理社会干预可以对公共卫生产生影响的观点。在这个节骨眼上,根据临床儿童和青少年心理学协会的标准,有数据支持儿科焦虑症的简短非药物干预[处方]可以被认为是行之有效的或可能有效的。此外,来自76项随机对照试验(N= 17,203名青少年)的数据对儿科焦虑结局(前后)的总体平均效应量为0.19。然而,请注意,效应大小差异很大。这些数据表明,临床变化的能力来自特定恐惧症的体内暴露(约3小时,一个疗程),CBT与社交技能培训(约3小时,六个疗程,用于指定的预防和早期干预),以及基于CBT的父母培训(约6小时,八个数字模块,有临床医生支持)。鉴于这些证据,我们建议努力建立方法,通过高质量的培训、监测、技术援助和持续披露,将这些治疗创新定位为快速部署。
In 1998, Ost published [One-session treatment of specific phobias–a rapid and effective method] [in Swedish] giving rise to the idea that brief, intensive, and concentrated psychosocial interventions could exhibit public health impact. At this juncture, and per criteria of the Society for Clinical Child and Adolescent Psychology, there are data supporting that brief, non-pharmacological intervention [prescriptions] for pediatric anxiety can be considered well-established or probably efficacious. In addition, data from 76 randomized controlled trials (N= 17,203 youth) yield an overall mean effect size of 0.19 on pediatric anxiety outcomes (pre-post). Note, however, that effect sizes vary significantly. These data point to the capacity for clinical change coming from in-vivo exposures for specific phobias (~3 h, one session), CBT with social skills training (~3 h, six sessions for indicated prevention and early intervention), and CBT-based parent training (~6 h, eight digital modules with clinician support). Given such evidence, we recommend efforts be made to establish ways to position such treatment innovations for rapid deployment facilitated by high-quality training, monitoring, technical assistance, and ongoing disclosures.